Collaboration to Drive PTC's Onshape Initiatives Including Discovery Program, Onshape AI Advisor, and CAD and PDM Conversion Tools BOSTON, Sept. 25, 2024 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced entry into a Strategic Collaboration Agreement (SCA) with Amazon Web Services (AWS) to accelerate the growth of its Onshape® cloud-native computer-aided design (CAD) and product data management (PDM) solution. This collaboration will focus on advancing Onshape product enhancements, customer adoption program ...

文章核心观点 - Roblox和PTC是两家表现不佳但仍有巨大增长潜力的公司 [1][2] - Roblox的用户数、营收和订阅量均呈现强劲增长 [3] - Roblox正在逐步发展其数字广告业务,并且用户群正在逐渐变老,这对广告主来说是有利因素 [4] - PTC的年度经常性收入(ARR)保持低双位数增长,这反映了其软件解决方案的持续需求 [5] - PTC可以利用其产品生命周期管理(PLM)、服务生命周期管理(SLM)等软件解决方案实现交叉销售 [6][7] - 尽管受经济环境影响,但PTC的ARR增长仍然可观,有望在经济好转时进一步提升 [7] Roblox公司分析 - Roblox的用户数、营收和订阅量均呈现强劲增长,用户群正在逐渐变老,这对广告主来说是有利因素 [3][4] - Roblox的在线游戏和社交平台已经证明具有持久性,其增长故事仍处于初期阶段 [4] PTC公司分析 - PTC的年度经常性收入(ARR)保持低双位数增长,反映了其软件解决方案的持续需求 [5] - PTC可以利用其产品生命周期管理(PLM)、服务生命周期管理(SLM)等软件解决方案实现交叉销售 [6][7] - 尽管受经济环境影响,但PTC的ARR增长仍然可观,有望在经济好转时进一步提升 [7]

SolStock PTC Therapeutics, Inc. (NASDAQ:PTCT) continues to make significant progress in its pipeline. This is especially true when you consider that it has already been able to report positive interim results from its phase 2 PIVOT-HD study, which used PTC518 for the treatment of patients with Huntington's Disease [HD]. The last time I wrote about this article in a Seeking Alpha article entitled "PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts," data for PTC518 was not released. Not o ...

BOSTON, Sept. 3, 2024 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that it has appointed Rob Bernshteyn to its Board of Directors, effective September 9, 2024. Bernshteyn has held leadership and executive roles in the enterprise software space for over 30 years, including 14 years as CEO and Chairman of Coupa Software, a provider of business spend management solutions. During his tenure at Coupa, Bernshteyn transformed the company into a high-growth industry leader and led a successful IPO in 2016. He ...

It has been about a month since the last earnings report for PTC Inc. (PTC) . Shares have added about 0.7% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is PTC Inc. due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. PTC's Q3 Earnings Meet Estimates PTC reported third ...

WARREN, N.J., Aug. 28, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: Morgan Stanley 22nd Annual Global Healthcare Conference Thursday, Sept. 5 at 9:15 am ET 2024 Wells Fargo Healthcare Conference Friday, Sept. 6 at 12:00 pm ET Cantor 2024 Global Healthcare Conference Tuesday, Sept. 17 at 2:30 pm ET The presentations will be webcast live on the Events and Presentations page under the Investor section o ...

BOSTON, Aug. 27, 2024 /PRNewswire/ -- PTC (Nasdaq: PTC) today announced that it will participate in the following conferences. What: Citi's 2024 Global TMT Conference When: Wednesday, September 4th, 2024 at 8:20am ET What: 2024 RBCCM Global TIMT Conference When: Tuesday, November 19th, 2024 What: Barclays 22nd Annual Global Technology Conference When: Wednesday, December 11th, 2024 What: Nasdaq 51st Investor Conference When: Wednesday, December 11th, 2024 To view the webcast and replay for conferences pleas ...

This industrial software company continues to grow its key metric and cash flow. Industrial software stock PTC (PTC 1.60%) is the sort of company investors should consider buying into on a dip. The company's recent third-quarter results, for the period ended June 30, and commentary on its fiscal 2025 were impressive in the current environment, and this company's long-term growth is only starting. Here's why PTC is a great stock for long-term holders. Attractive end markets PTC's software solutions help cust ...

– Continued strong revenue performance – – NDAs for sepiapterin and Translarna™ submitted to FDA – – Positive interim data readout from PTC518 PIVOT-HD study – – On track to achieve remaining 2024 clinical and regulatory milestones – WARREN, N.J., Aug. 8, 2024 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the second quarter ending June 30, 2024. "I am proud of our team's continued outstanding execution as we have accomplished all our obje ...

文章核心观点 - PTC Inc.第二季度营收为5.186亿美元,同比下降4.4% [1] - 每股收益为0.98美元,与去年同期的0.99美元相比基本持平 [1] - 公司营收低于市场预期,但每股收益符合预期 [2] 公司财务数据总结 经营数据 - 年度经常性收入(ARR)为21.3亿美元,符合分析师预期 [6] - 经常性收入为4.816亿美元,低于分析师预期的4.991亿美元,同比下降3.4% [7] - 专业服务收入为3,003万美元,高于分析师预期的2,845万美元,同比下降15.8% [8] - 软件总收入(包括许可和支持&云服务)为4.886亿美元,低于分析师预期的5.047亿美元,同比下降3.6% [9] - 永续许可收入为705万美元,高于分析师预期的560万美元,同比下降14.6% [10] 股价表现 - 公司股价在过去一个月内下跌4.4%,低于标普500指数下跌0.4% [11] - 公司目前评级为中性(Zacks Rank 3),意味着短期内可能与大盘持平 [11]